Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Cash from Investing Activities (2016 - 2025)

Editas Medicine (EDIT) has disclosed Cash from Investing Activities for 11 consecutive years, with $39.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Investing Activities fell 52.88% to $39.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $169.6 million, a 12.61% decrease, with the full-year FY2024 number at $162.1 million, up 4445.91% from a year prior.
  • Cash from Investing Activities was $39.6 million for Q3 2025 at Editas Medicine, down from $42.6 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $89.2 million in Q3 2022 to a low of -$102.8 million in Q3 2023.
  • A 5-year average of $18.8 million and a median of $23.3 million in 2023 define the central range for Cash from Investing Activities.
  • Peak YoY movement for Cash from Investing Activities: surged 1637.7% in 2022, then tumbled 215.23% in 2023.
  • Editas Medicine's Cash from Investing Activities stood at -$22.8 million in 2021, then fell by 20.53% to -$27.5 million in 2022, then surged by 328.28% to $62.8 million in 2023, then plummeted by 50.74% to $31.0 million in 2024, then grew by 27.83% to $39.6 million in 2025.
  • Per Business Quant, the three most recent readings for EDIT's Cash from Investing Activities are $39.6 million (Q3 2025), $42.6 million (Q2 2025), and $56.4 million (Q1 2025).